Product Overview
Retatrutide, also known as LY3437943, is a triple agonist developed to activate GLP-1, GIP, and glucagon receptors. That makes it a major step beyond traditional single-pathway GLP-1 research.
Each pathway brings something different to the table: GLP-1 is associated with appetite signaling, gastric activity, insulin response, and glucose regulation; GIP with nutrient signaling, insulin activity, and lipid metabolism; and glucagon with energy expenditure, hepatic metabolism, and substrate utilization.
Together, these pathways give researchers a more complete metabolic model than studying each receptor independently. For projects comparing single, dual, and triple agonist systems, retatrutide represents one of the most advanced compounds currently under investigation.
Common Research Areas
⦁ Appetite and satiety pathways
⦁ Glucose and insulin signaling
⦁ Energy expenditure
⦁ Lipid and hepatic metabolism
⦁ Body-weight and body-composition research
Research References
- Coskun T, et al. “LY3437943, a novel triple glucagon, GLP-1 and GIP receptor agonist for the potential treatment of diabetes mellitus and obesity.” Molecular Metabolism. 2022;60:101474. DOI: 10.1016/j.molmet.2022.101474.
- Jastreboff AM, et al. “Efficacy and Safety of Retatrutide in People with Obesity: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2 Trial.” The New England Journal of Medicine. 2023;389(6):514-526. DOI: 10.1056/NEJMoa2206038.
